Nasdaq · Biotech stocks database
AAPG — Ascentage Pharma Group International ☆
AAPG (Ascentage Pharma Group International) stock: $15.43, $1.44B market cap, $122.3M cash, $1.57B EV, $1.46B fully diluted market cap. Data from Fully Diluted's biotech stocks database.
Overview
Catalysts
Assets
Pipeline
Trials
Holders
News
What they do
We are a global, commercial stage, integrated biopharmaceutical company engaged in the discovery, development and commercialization of novel, differentiated therapies to address unmet medical needs in cancer. For more than two decades, our founders and team have leveraged their deep expertise to develop our proprietary drug discovery platform to pursue particularly challenging targets and significant unmet global medical needs.
Source: 20-F FY2025 via SEC EDGAR
Enterprise value
$1,567.3M
Balance sheet
Cash $122.3M Debt $249.5M Net cash -$127.2M Enterprise value $1,567.3M Basic shares 93.3M shares Fully diluted shares 94.4M shares Fully diluted market cap $1,456.8M Cash per share $1.31 Quarterly burn $3.8M Cash runway 35.0 quarters
Cash figures as of 2024-12-31. Database snapshot: 2026-11-07.
Share structure
Cap table as of 2025-12-31.
Price history Loading AAPG daily closes…
Loading price history…
Next catalyst APG2575 · Jan 12 - Feb 23 in 9 wks · Phase 2 · Chronic Lymphocytic Leukemia; Small Lymphocytic LymphomaAll upcoming catalysts (+15 more) →
Upcoming catalysts Expected Drug Phase Indication Mgmt guide Jan 12 - Feb 23 in 9 wks APG2575 Phase 2 Chronic Lymphocytic Leukemia; Small Lymphocytic Lymphoma — Feb 11 - Mar 25 in 14 wks lisaftoclax Phase 3 CLL/SLL — May 12 - Jun 23 in 6 mo Olverembatinib Phase 3 GIST — Jun 12 - Jul 24 in 7 mo APG -2449 Phase 1 Platinum-resistant Recurrent Ovarian Cancer; Advanced Solid Tumor — Jul 13 - Aug 24 in 8 mo APG-115 Phase 1/2 Neuroblastoma; Solid Tumor — Aug 11 - Sep 22 in 9 mo olverembatinib Phase 3 Chronic Myeloid Leukemia; CML; CML, Chronic Phase — Sep 12 - Oct 24 in 10 mo Lisaftoclax (APG-2575) Phase 3 CLL/SLL — Jan 12 - Feb 23 in 14 mo HQP1351 Phase 1 Gastrointestinal Stromal Tumor (GIST); Solid Tumor, Adult — Jan 12 - Feb 23 in 14 mo APG-2449 Phase 1 Advanced Solid Cancer; Non Small Cell Lung Cancer; Esophageal Cancer — Feb 11 - Mar 24 in 15 mo Olverembatinib Phase 3 Ph+ ALL; Leukemia, Lymphoblastic, Acute, Philadelphia-Positive — Feb 11 - Mar 24 in 15 mo APG-5918 Phase 1 Anemia — Jul 6 - Aug 17 in 20 mo APG-2575(Lisaftoclax ) Phase 3 Acute Myeloid Leukemia — Oct 13 - Nov 24 in 24 mo Lisaftoclax (APG-2575) Phase 1/2 Relapsed/Refractory Acute Myeloid Leukaemia; Myeloid Malignancy — Jul 13 - Aug 24 in 33 mo Lisaftoclax (APG-2575) Phase 3 Higher-risk Myelodysplastic Syndrome — Jan 12 - Feb 23 in 39 mo APG-3288 Phase 1 Relapsed/Refractory Hematological Malignancies; Relapsed/Refractory Chronic Lymphocytic Leukemia/Small Lymphocytic Leu; Relapsed/Refractory Diffuse Large B-cell Lymphoma (DLBCL; Including Ri — Feb 7 - Mar 21 in 40 mo Ascentage Pharma HQP1351 bioavailable inhibitor Phase 1 Leukemia, Myeloid, Chronic; Myeloid Leukemia; Chronic Myeloid Leukemia —
Estimated readout windows: registry primary-completion date + 6-12 weeks. Windows already open are shown from "Now". Drug names link to ClinicalTrials.gov.
Full readout calendar →
Pipeline assets Olverembatinib
Approved · Active
Target BCR-ABL1
Indications Chronic myeloid leukemia (CML-CP with T315I; CML-AP with T315I; CML-CP resistant/intolerant to 1st/2nd-gen TKIs) (Approved) Status note Commercialized in China per this 20-F; no per-candidate target, modality, indication detail or pipeline table in the excerpts.
Lisaftoclax
Approved · Active
Target Bcl-2
Indications Relapsed/refractory CLL/SLL (adults, prior systemic therapy incl. BTK inhibitor) (Approved) Status note Commercialized in China per this 20-F; no per-candidate target, modality, indication detail or pipeline table in the excerpts.
Per-asset detail extracted from the 20-F filed 2026-04-29. Fields the filing does not state are marked "not disclosed" rather than filled from other sources.
No lead program on file for this company.
Active clinical trials Trial Phase Status Role Sponsor BP Condition(s) Mgmt guide NCT06104566 Phase 3 Recruiting Sponsor Ascentage Pharma Group Inc. — CLL/SLL — NCT06640361 Phase 3 Recruiting Sponsor Ascentage Pharma Group Inc. — GIST — NCT06423911 Phase 3 Recruiting Sponsor Ascentage Pharma Group Inc. — Chronic Myeloid Leukemia; CML; CML, Chronic Phase — NCT06319456 Phase 3 Recruiting Sponsor Ascentage Pharma Group Inc. — CLL/SLL — NCT06051409 Phase 3 Recruiting Sponsor Ascentage Pharma Group Inc. — Ph+ ALL; Leukemia, Lymphoblastic, Acute, Philadelphia-Positive — NCT06389292 Phase 3 Recruiting Sponsor Ascentage Pharma Group Inc. — Acute Myeloid Leukemia — NCT06641414 Phase 3 Recruiting Sponsor Ascentage Pharma Group Inc. — Higher-risk Myelodysplastic Syndrome — NCT05147467 Phase 2 Recruiting Sponsor Ascentage Pharma Group Inc. — Chronic Lymphocytic Leukemia; Small Lymphocytic Lymphoma — NCT04496349 Phase 2 Recruiting Sponsor Ascentage Pharma Group Inc. — T-Prolymphocytic Leukemia; Non-Hodgkins Lymphoma — NCT05701306 Phase 1/2 Recruiting Sponsor Ascentage Pharma Group Inc. — Neuroblastoma; Solid Tumor — NCT04501120 Phase 1/2 Recruiting Sponsor Ascentage Pharma Group Inc. — Relapsed/Refractory Acute Myeloid Leukaemia; Myeloid Malignancy — NCT04494503 Phase 1/2 Recruiting Sponsor Ascentage Pharma Group Inc. — Chronic Lymphocytic Leukemia; Small Lymphocytic Lymphoma —
Sponsor-matched active trials from ClinicalTrials.gov (26 as sponsor, 4 as collaborator); "Sponsor" = company is the lead sponsor, "Collaborator" = company is a collaborator. The BP column flags big-pharma involvement as lead sponsor or collaborator (excluding the company itself). The Mgmt guide column shows what management guided for readout timing when a guided program matches the trial (hover for the quote, click for the source). Trial listings are not a company pipeline slide.
View all 30 active trials for Ascentage Pharma Group Inc. on ClinicalTrials.gov
Specialist fund holders Tracked specialist funds: ADAR1 Capital Management, Aisling Capital, Ally Bridge Group, Avoro Capital Advisors, BVF Partners, Baker Bros. Advisors, Boxer Capital, Braidwell LP, Casdin Capital, Cormorant Asset Management, DAFNA Capital, Deerfield Management, EcoR1 Capital, Frazier Life Sciences, Great Point Partners, Ikarian Capital, Logos Global Management, OrbiMed Advisors, Perceptive Advisors, RA Capital Management, RTW Investments, Sphera Biotech, Stonepine Capital, Tang Capital Partners, Vivo Capital.
None of the tracked specialist funds reported a position in the latest 13F snapshot.
Fully Diluted · Free biotech stocks database. Figures are sourced from SEC filings and company disclosures; not investment advice.